ProKidney Corp. Research and Development Expense
ProKidney Corp. (PROK) reported Research and Development Expense of $36.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- ProKidney Corp. research and development expense for the quarter ending 2026-06-30 was $36.09M, a 39.46% increase year-over-year.
- ProKidney Corp. research and development expense for the quarter ending 2026-03-31 was $33.84M, a 24.13% increase year-over-year.
- ProKidney Corp. research and development expense for the quarter ending 2025-12-31 was $34.16M, a 14.14% decline year-over-year.
- ProKidney Corp. research and development expense for the quarter ending 2025-09-30 was $26.82M, a 14.17% decline year-over-year.
- ProKidney Corp. research and development expense for fiscal 2025 was $114.12M, a 10.61% decline from fiscal 2024.
- ProKidney Corp. research and development expense for fiscal 2024 was $127.67M, a 19.64% increase from fiscal 2023.
- ProKidney Corp. research and development expense for fiscal 2023 was $106.71M, a 30.02% increase from fiscal 2022.
- ProKidney Corp. research and development expense for fiscal 2022 was $82.07M, a 77.43% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.09M 10-Q · filed 2026-08-10 | $69.94M 10-Q · filed 2026-08-10 | $104.09M derived: sum of 3 quarters · filed 2026-08-10 | $130.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $33.84M 10-Q · filed 2026-05-15 | $68.00M derived: sum of 2 quarters · filed 2026-05-15 | $94.82M derived: sum of 3 quarters · filed 2026-05-15 | $120.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $34.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $60.98M derived: sum of 2 quarters · filed 2026-03-18 | $86.86M derived: sum of 3 quarters · filed 2026-08-10 | $114.12M 10-K · filed 2026-03-18 |
| 2025-09-30 | $26.82M 10-Q · filed 2025-11-10 | $52.70M derived: sum of 2 quarters · filed 2026-08-10 | $79.97M 10-Q · filed 2025-11-10 | $119.75M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $25.88M 10-Q · filed 2026-08-10 | $53.15M 10-Q · filed 2026-08-10 | $92.93M derived: sum of 3 quarters · filed 2026-08-10 | $124.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $27.26M 10-Q · filed 2026-05-15 | $67.04M derived: sum of 2 quarters · filed 2026-05-15 | $98.29M derived: sum of 3 quarters · filed 2026-05-15 | $127.70M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $39.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $71.03M derived: sum of 2 quarters · filed 2026-03-18 | $100.44M derived: sum of 3 quarters · filed 2026-03-18 | $127.67M 10-K · filed 2026-03-18 |
| 2024-09-30 | $31.25M 10-Q · filed 2025-11-10 | $60.65M derived: sum of 2 quarters · filed 2025-11-10 | $87.89M 10-Q · filed 2025-11-10 | $110.42M derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-06-30 | $29.40M 10-Q · filed 2025-08-12 | $56.64M 10-Q · filed 2025-08-12 | $79.17M derived: sum of 3 quarters · filed 2026-03-18 | $111.36M derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-03-31 | $27.23M 10-Q · filed 2025-05-12 | $49.76M derived: sum of 2 quarters · filed 2026-03-18 | $81.96M derived: sum of 3 quarters · filed 2026-03-18 | $108.32M derived: sum of 4 quarters · filed 2026-03-18 |
| 2023-12-31 | $22.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $54.73M derived: sum of 2 quarters · filed 2026-03-18 | $81.09M derived: sum of 3 quarters · filed 2026-03-18 | $106.71M 10-K · filed 2026-03-18 |
| 2023-09-30 | $32.20M 10-Q · filed 2024-11-12 | $58.56M derived: sum of 2 quarters · filed 2024-11-12 | $84.18M 10-Q · filed 2024-11-12 | $105.07M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $26.36M 10-Q · filed 2024-08-09 | $51.98M 10-Q · filed 2024-08-09 | $72.87M derived: sum of 3 quarters · filed 2025-03-17 | $94.00M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $25.62M 10-Q · filed 2024-05-10 | $46.51M derived: sum of 2 quarters · filed 2025-03-17 | $67.64M derived: sum of 3 quarters · filed 2025-03-17 | $79.20M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $20.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $42.02M derived: sum of 2 quarters · filed 2025-03-17 | $53.58M derived: sum of 3 quarters · filed 2025-03-17 | $82.07M 10-K · filed 2025-03-17 |
| 2022-09-30 | $21.13M 10-Q · filed 2023-11-14 | $32.69M derived: sum of 2 quarters · filed 2023-11-14 | $61.18M 10-Q · filed 2023-11-14 | $71.86M derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-06-30 | $11.56M 10-Q · filed 2023-08-10 | $40.05M 10-Q · filed 2023-08-10 | $50.73M derived: sum of 3 quarters · filed 2024-03-22 | $65.47M derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-03-31 | $28.49M 10-Q · filed 2023-05-11 | $39.17M derived: sum of 2 quarters · filed 2024-03-22 | $53.92M derived: sum of 3 quarters · filed 2024-03-22 | |
| 2021-12-31 | $10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $25.43M derived: sum of 2 quarters · filed 2024-03-22 | $46.26M 10-K · filed 2024-03-22 | |
| 2021-09-30 | $14.74M 10-Q · filed 2022-11-14 | $35.57M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $21.04M 10-K · filed 2023-03-28 |